Zobrazit minimální záznam

TET protein inhibitors: Potential and limitations

dc.contributor.authorKaplánek, Robert
dc.contributor.authorKejík, Zdeněk
dc.contributor.authorHajduch, Jan
dc.contributor.authorVeselá, Kateřina
dc.contributor.authorKučnirová, Kateřina
dc.contributor.authorSkaličková, Markéta
dc.contributor.authorVenhauerová, Anna
dc.contributor.authorHosnedlová, Božena
dc.contributor.authorHromádka, Róbert
dc.contributor.authorDytrych, Petr
dc.contributor.authorNovotný, Petr
dc.contributor.authorAbramenko, Nikita
dc.contributor.authorAntonyová, Veronika
dc.contributor.authorHoskovec, David
dc.contributor.authorBabula, Petr
dc.contributor.authorMasařík, Michal
dc.contributor.authorMartásek, Pavel
dc.contributor.authorJakubek, Milan
dc.date.accessioned2023-10-25T12:10:28Z
dc.date.available2023-10-25T12:10:28Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.14178/2055
dc.description.abstractTET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.1016/j.biopha.2023.115324
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titleTET protein inhibitors: Potential and limitationsen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2023-11-07T08:13:41Z
dc.subject.keywordTET proteinen
dc.subject.keywordInhibitoren
dc.subject.keywordCanceren
dc.subject.keywordTherapyen
dc.subject.keywordMitochondriaen
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/SVV/SVV260521
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/UNCE/MED/UNCE/MED/007
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/LM/LM2023053
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/COOP/COOP
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/PROGRES/Q26
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/PROGRES/Q27
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/TA0/TN/TN01000013
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/TA0/TN/TN02000109
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/TA0/FW/FW02020128
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU22-D-136
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/FN/I-FN/RVO-VFN64165
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5107
dc.date.embargoStartDate2023-11-07
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.1016/j.biopha.2023.115324
dc.identifier.utWos001060916100001
dc.identifier.eidScopus2-s2.0-85168132692
dc.identifier.obd634324
dc.identifier.pubmed37598475
dc.subject.rivPrimary30000::30200::30204
dcterms.isPartOf.nameBiomedicine & Pharmacotherapy
dcterms.isPartOf.issn0753-3322
dcterms.isPartOf.journalYear2023
dcterms.isPartOf.journalVolume166
dcterms.isPartOf.journalIssueOctober
uk.faculty.primaryId108
uk.faculty.primaryName1. lékařská fakultacs
uk.faculty.primaryNameFirst Faculty of Medicineen
uk.faculty.secondaryId53
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazecs
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazeen
uk.department.primaryId108
uk.department.primaryName1. lékařská fakultacs
uk.department.primaryNameFirst Faculty of Medicineen
uk.department.secondaryId1522
uk.department.secondaryId5000002594
uk.department.secondaryId1496
uk.department.secondaryId1508
uk.department.secondaryId5000002603
uk.department.secondaryId100025448551
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1. LF a VFNcs
uk.department.secondaryNameDepartment of Paediatrics and Inherited Metabolic Disorders 1. LF UK a VFNen
uk.department.secondaryNameI. chirurgická klinika - břišní, hrudní a úrazová chirurgie 1.LF a VFNcs
uk.department.secondaryNameI. chirurgická klinika - břišní, hrudní a úrazová chirurgie 1.LF a VFNen
uk.department.secondaryNameÚstav patologické fyziologie 1. LF UKcs
uk.department.secondaryNameInstitute of Pathological Physiologyen
uk.department.secondaryNameI. chirurgická klinika – břišní, hrudní a úrazové chirurgie 1. LF UK a VFNcs
uk.department.secondaryName1st Department of Surgery – Department of Abdominal, Thoracic Surgery and Traumatologyen
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNcs
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNen
uk.department.secondaryNameBIOCEV 1. LF UKcs
uk.department.secondaryNameBIOCEVen
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::přehledový článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::summarizing articleen
dc.type.obdHierarchyCode73::152::205en
uk.displayTitleTET protein inhibitors: Potential and limitationsen


Soubory tohoto záznamu

Thumbnail
Název:
634324.pdf
Velikost:
3.442Mb
Formát:
PDF
Zobrazit/otevřít

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam